Correction to: Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program

Marjorie A. Speers¹

Published online: 4 July 2020
© Springer Nature Switzerland AG 2020

Correction to: *Pharmaceutical Medicine* (2019) 33:89–98
<https://doi.org/10.1007/s40290-019-00274-3>

Page 96, reference list: Reference 24, which previously read:

24. Van Norman G. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. *J Am Coll Cardiol Basic Trans Science*. 2016;1:170–9.

should read:

24. Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. *JACC Basic Transl Sci*. 2016;1(3):170–9.

Page 97, reference list: Reference 68, which previously read:

68. Norman GA. Expanding patient access to investigational drugs. Single patient investigational new drug and the “right to try”. *JACC:Basic Transl Sci*. 2018;3(2):280–93.

should read:

68. Van Norman GA. Expanding patient access to investigational drugs: Single patient investigational new drug and the “right to try”. *JACC Basic Transl Sci*. 2018;3(2):280–93.

The original article can be found online at <https://doi.org/10.1007/s40290-019-00274-3>.

✉ Marjorie A. Speers
mspeers@clinicalresearchpathways.org

¹ Clinical Research Pathways, 245 N Highland Ave, Suite 230, Atlanta, GA 30307, USA